



Sydney, Australia, Wednesday, March 24, 2010.

MEDIA RELEASE

PHEBRA'S LIFE SAVING CAFFEINE MEDICINE TO TREAT APNOEA IN PREMATURE BABIES

Australian owned pharmaceutical company, Phebra, has developed a new life saving medicine which will be used to treat potentially thousands of premature Australian babies suffering apnoea, it was announced today.

Phebra Chief Executive Officer, Dr Mal Eutick OAM, said the Australian Therapeutic Goods Administration (TGA) had granted the marketing approval of CAFNEA™ (caffeine citrate) Injection and Oral Solution.

CAFNEA™ is approved for the short term treatment of apnoea in premature infants between 28 and 33 week's gestational age.

Pre-term apnoea is a pause of breathing of more than 20 seconds and can occur recurrently in a proportion of premature babies. It may be harmful to the developing brain and organs.

"We are delighted to have gained marketing approval for CAFNEA™," Dr Eutick said today.

"CAFNEA™ is a life saving medicine for premature infants and Phebra is pleased to be making a contribution to the treatment of such a harmful condition in Australia and overseas."

"Many premature babies with breathing difficulties may now be treated with CAFNEA™, which may offer an improved safety profile to the previously used products."

According to the Australian Institute of Health and Welfare, approximately 5,590 babies were born between 28 and 33 week's gestational age in 2007.

CAFNEA™ is available in the following presentations:

- CAFNEA Injection: 20mg caffeine base in 2mL single use vials in boxes of 10.
- CAFNEA Oral Solution: 12.5mg caffeine base in 5mL single use vials in boxes of 10.

Dr Eutick said Phebra was granted Orphan Drug Designation from the TGA for CAFNEA Injection and Oral Solution in August 2007. Phebra is an Australian based specialty pharmaceutical company that develops and markets critical medicines in Australia, New Zealand, Asia, Canada and parts of Europe.

At Phebra, we create critical medicines that save and improve lives.

For further information, please call:

Eve Williamson: + 61 (0) 418 892 287.

Vice President, Business Development, Marketing and Sales.

Phebra Pty Ltd
332 Burns Bay Road, Lane Cove NSW 2066 Australia
Locked Bag 3003, Hunters Hill NSW 2110 Australia
T +61 (0)2 9420 9199 F +61 (0)2 9420 9177 W www.phebra.com
ABN 77 695 661 635